Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M3Receptor‐Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers

Autor: Takusagawa, Shin, Treijtel, Nicoline, Saito, Masako, Michon, Ingrid, Miyatake, Daisuke, Osaki, Fumio, Guro, Sayuri, Fadini, Tomasso, Sekino, Hisakuni, Aarden‐Bakker, Marlous, Kuroishi, Kentaro, Till, Jan Willem Olivier, Groenendaal‐van de Meent, Dorien, Vries, Michiel

Publikováno v: Clinical Pharmacology in Drug Development; October 2024, Vol. 13 Issue: 10 p1130-1142, 13p

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M 3 Receptor-Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers.

Autor: Takusagawa S; Astellas Pharma Inc., Tokyo, Japan., Treijtel N; Astellas Pharma Europe B.V., Leiden, The Netherlands., Saito M; Astellas Pharma Inc., Tokyo, Japan., Michon I; Astellas Pharma Europe B.V., Leiden, The Netherlands., Miyatake D; Astellas Pharma Inc., Tokyo, Japan., Osaki F; Astellas Pharma Inc., Tokyo, Japan., Guro S; Astellas Pharma Inc., Tokyo, Japan., Fadini T; PAREXEL International, Berlin, Germany., Sekino H; Sekino Clinical Pharmacology Clinic, Tokyo, Japan., Aarden-Bakker M; Astellas Pharma Europe B.V., Leiden, The Netherlands., Kuroishi K; Astellas Pharma Inc., Tokyo, Japan., van Till JWO; Mitobridge Inc., Cambridge, MA, USA., Groenendaal-van de Meent D; Astellas Pharma Europe B.V., Leiden, The Netherlands., de Vries M; Astellas Pharma Europe B.V., Leiden, The Netherlands.

Publikováno v: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2024 Oct; Vol. 13 (10), pp. 1130-1142. Date of Electronic Publication: 2024 Aug 09.